<DOC>
	<DOCNO>NCT02012218</DOCNO>
	<brief_summary>The objective exploratory trial evaluate efficacy , safety , subject ' subjective satisfaction switch adjunctive brexpiprazole subject MDD respond inadequately precede adjunctive drug therapy .</brief_summary>
	<brief_title>Brexpiprazole Adjunctive Therapy With Major Depressive Disorder Inadequate Response Previous Adjunctive Therapy</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Clinical diagnosis MDD In current major depressive episode ≥ 8 week duration include inadequate response least 1 adjunctive treatment . Positive history least 1 additional failure adequate monotherapy antidepressant treatment . HAMD17 total score≥ 18 Currently receive SSRI SNRI adjunctive treatment least 6 week screen . Willing discontinue use prohibit psychotropic medication Historical positive serological result HIV , hepatitis B/C Able provide write informed consent prior initiation protocolrequired procedure Subjects could potentially benefit adjunctive treatment Brexpiprazole Sexually active woman childbearing potential Male subject practice 2 different method birth control Females breastfeed and/or positive pregnancy test result Subjects receive ECT current major depressive episode . Subjects inadequate response ECT Current need involuntary commitment hospitalize within 4 week screen Current Axis I ( DSMIVTR ) Current Axis II ( DSMIVTR ) Subjects experience hallucination , delusion , psychotic symptomatology current major depressive episode . Subjects receive new onset psychotherapy . Subjects answer `` Yes '' CSSRS Suicidal Ideation Item 4 , Item 5 , 5 CSSRS Suicidal Behavior Items Subjects meet DSMIVTR criterion substance abuse dependence within past 180 day Hypothyroidism hyperthyroidism Clinically significant neurological , hepatic , renal , metabolic , haematological , immunological , cardiovascular , pulmonary , gastrointestinal disorder Currently treat insulin diabetes Uncontrolled hypertension symptomatic hypotension , orthostatic hypotension Known ischemic heart disease history myocardial infarction , congestive heart failure , angioplasty , stenting , coronary artery bypass surgery Epilepsy history seizure Positive drug screen The following laboratory test ECG result exclusionary : 1 . Platelets ≤ 75,000/mm3 2 . Hemoglobin ≤ 9 g/dL 3 . Neutrophils , absolute ≤ 1000/mm3 4 . AST &gt; 2 × ULN 5 . ALT &gt; 2 × ULN 6 . CPK &gt; 3 × ULN , unless discuss approve medical monitor 7 . Creatinine ≥ 2 mg/dL 8 . HbA1c ≥ 7.0 % 9 . Abnormal free T4 ( Note : Free T4 measure result TSH abnormal . ) 10 . QTcF ≥ 470 msec female ≥ 450 msec male Treatment MAOI EMSAM within 14 day Baseline visit . Use benzodiazepines and/or hypnotic within 7 day prior first dose IMP Use oral neuroleptic within 7 day prior longacting approve atypical antipsychotic ≤ 1 full cycle plus ½ cycle prior first dose IMP Subjects would likely require prohibited concomitant therapy trial . Subjects previously participate prior brexpiprazole trial History neuroleptic malignant syndrome serotonin syndrome History true allergic response one class medication Prisoners subject compulsorily detain treatment either psychiatric physical illness . Subjects participate clinical trial within last 180 day participate 2 clinical trial within past year . Any subject , opinion investigator medical monitor , participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Major Depressive Disorder , Depression</keyword>
</DOC>